Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Intervacc AB's share price for the quarter that ended in Mar. 2026 was €0.0257. Intervacc AB's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 340.81 Mil. Therefore, Intervacc AB's market cap for the quarter that ended in Mar. 2026 was €8.76 Mil.
Intervacc AB's quarterly market cap
declined
from Sep. 2025 (€13.77 Mil) to Dec. 2025 (€11.59 Mil) and
declined
from Dec. 2025 (€11.59 Mil) to Mar. 2026 (€8.76 Mil).
Intervacc AB's annual market cap
declined
from Dec. 2023 (€44.40 Mil) to Dec. 2024 (€3.08 Mil) but then
increased
from Dec. 2024 (€3.08 Mil) to Dec. 2025 (€11.59 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Intervacc AB's Enterprise Value for Today is €27.15 Mil.
Intervacc AB (FRA:2E9) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Intervacc AB Market Cap Related Terms
Intervacc AB Market Cap Historical Data
* Premium members only.
The historical data trend for Intervacc AB's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2E9 vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Intervacc AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intervacc AB Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Intervacc AB's Market Cap distribution charts can be found below:
* The bar in red indicates where Intervacc AB's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Intervacc AB's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intervacc AB (FRA:2E9) has a Market Cap of €41.63 Mil as of Jul. 02, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Intervacc AB and its competitors. According to the industry distribution chart, Intervacc AB ranks #909 out of 1427 companies in the Biotechnology industry, placing it in the top 63.7%.
Is Intervacc AB's Market Cap too high?
Intervacc AB's current Market Cap is €41.63 Mil. Based on the distribution chart, Intervacc AB ranks #909 out of 1427 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Intervacc AB has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Intervacc AB's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Intervacc AB ranks #909 out of 1427 companies for Market Cap. This places Intervacc AB in the lower half of its industry. The industry median Market Cap is 119.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.04, based on 1,427 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Intervacc AB and its competitors. For the Biotechnology industry, the median Market Cap is 119.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intervacc AB's current Market Cap is €41.63 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intervacc AB stock overvalued right now?
Intervacc AB (FRA:2E9) has a current Market Cap of €41.63 Mil. The stock's GF Value™ is €0.06, compared to a current price of €0.07 — trading 12.5% above its estimated fair value. The current Market Cap is €41.63 Mil. Intervacc AB's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Intervacc AB (FRA:2E9), the current Market Cap is €41.63 Mil as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Intervacc AB (FRA:2E9) Overvalued in 2026?
Based on GuruFocus' analysis, Intervacc AB stock appears to be overvalued.
The current stock price of €0.07 is trading 12.5% above its estimated GF Value™ of €0.06.
Key valuation signals for FRA:2E9:
Market Cap: €41.63 Mil
GF Value™: €0.06 vs. price of €0.07 (12.5% above fair value)
No single metric tells the full story. See the FRA:2E9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Intervacc AB is a biotechnology company. It develops new vaccines based on recombinant proteins to meet the increasing need for effective vaccines in animal health care. The company through its subsidiary focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses on the Swedish market.
62GF Score
Get the complete analysis for FRA:2E9
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2E9 has been successfully added to your 
